Accession Number : AD1048459

Title :   Phase I Trial of Intratumoral Administration of NIS-Expressing Strain of Measles Virus in Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor

Descriptive Note : Technical Report,15 Sep 2016,14 Sep 2017

Corporate Author : Mayo Clinic And Foundation Rochester United States

Personal Author(s) : Babovic-Vuksanovic,Dusica

Full Text :

Report Date : 01 Oct 2017

Pagination or Media Count : 10

Abstract : Study approved by Mayo IRB on April 18, 2016, and by USAMRMC/ORP/HRPO on May 6, 2016. All study staff completed IRB training. Dose volume charts have been developed to facilitate pharmacy orders. Study opened for enrollment on May 17, 2016. Study coordinators identified and assigned to the study by Mayo Clinic Cancer Center. Three patients have been enrolled in the study. They completed treatment per protocol and continue the follow up. None of the treated patients experienced side effects. With the first 3 patients we have completed the first dose level. We are continuing recruitment for the second dose level.

Descriptors :   clinical trials , neoplasms , dose rate , safety , gene expression , viruses

Subject Categories : Medicine and Medical Research
      Genetic Engineering and Molecular Biology

Distribution Statement : APPROVED FOR PUBLIC RELEASE